Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Biotechnology company Exelixis has announced that its recently completed multi-site Phase II trial of an investigational drug did not met its primary endpoint of reducing proteinuria compared with placebo in patients with proteinuria associated with diabetic nephropathy.
Subscribe to our email newsletter
Exelixis is continuing to analyze the data to assess whether further evaluation of the compound is warranted. The results of the potent small molecule inhibitor, XL784 meet the criteria for submission of the compound to GlaxoSmithKline (GSK) for evaluation under the product development and commercialization agreement between Exelixis and GSK.
George Scangos, president and CEO of Exelixis, said: “We obviously are disappointed that this trial did not meet its primary endpoint. However, the compound was well tolerated, and we are continuing to analyze the data to determine if the compound may have utility in the treatment of diabetic nephropathy. We will provide an update on our plans for XL784 once we complete our analysis of the data.”